Ten Bridge worked with Myovant Sciences ahead of the FDA approval and commercial launch of Orgovyx, the first oral therapy to be approved for prostate cancer. The availability of an oral therapy for prostate cancer promised to provide enhanced quality of life for patients and the milestone marked the first approval for the company.
- Media strategy and execution
- Multimedia asset development
- Regulatory milestones
Laying the foundation
In the months leading up to the anticipated FDA decision, Ten Bridge worked with Myovant to plan for various FDA decision scenarios. We developed a narrative and media campaign to be executed with a positive decision and product launch focused on communicating the benefits of an oral therapy for prostate cancer and driving understanding and adoption of a new therapy by communicating accurate and timely label information. Another goal was to position Orgovyx as the first drug in Myovant’s pipeline of therapeutics based on its core relugolix MOA
Breaking through – even in the most competitive of news environments
With the PDUFA date approaching in late 2020 and given the FDA’s focus on COVID therapeutics at the time, TBC prepared for a comprehensive media campaign around the approval, including the creation of multimedia assets and materials to arm the media to cover the news in a timely and accurate manner. With this diligent preparation and execution, TBC was able to secure cross-channel earned media coverage that effectively communicated the benefits of an oral therapy and the availability of a new solution for patients with prostate cancer.